PRESS RELEASE

CARMAT announces the registration of its Document de Base with the Autorité des marchés financiers (AMF), the French market authority, within the context of its planned IPO on the Alternext market of NYSE-Euronext Paris

Paris, 25 May 2010:

CARMAT, innovative medtech developing the world’s most advanced total artificial heart, announces the registration of its Document de Base with the “Autorité des marchés financiers” (AMF), the French stock market authority, under reference number I.10-037 on May 21st, 2010, within the context of its planned IPO on the Alternext market of NYSE-Euronext Paris.

The registration of the Document de Base is the first step towards an Initial Public Offering of CARMAT’s shares on the Alternext market, which is expected to take place shortly, subject to market conditions after approval of the offer prospectus by the AMF. CARMAT's IPO on the Alternext market of NYSE-Euronext Paris will enable the Company to accelerate its development.

CARMAT, the world’s most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of the combination of two types of expertise that are unique in the world: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, save tens of thousands of patients’ lives a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.
Numerous tried and tested technological breakthroughs: the CARMAT artificial heart has already been the subject of thousands of hours of simulations and wear-and-tear tests giving it a lifespan of more than 5 years. Indeed, the CARMAT total artificial heart will have similar reliability to that of an aeroplane making its maiden flight.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

Substantial involvement of prestigious shareholders: Truffle Capital, the leading European venture capital firm, EADS and the Fondation Alain Carpentier.

Availability of the source document – The Document de Base registered on May 21st, 2010 under number I.10-037 is available, free of charge and on demand, from CARMAT, Direction Administrative et financière, 36 avenue de l’Europe – CS 40533 – 78941 Vélizy Villacoublay Cedex, FRANCE, as well as on the websites of the “Autorité des marchés financiers”, the French stock market authority (www.amf-france.org) and CARMAT(www.carmatsas.com/investisseurs).

Risk factors - CARMAT draws the attention of the public to the “risk factors” section in its Document de Base registered with the “Autorité des marchés financiers”. These risk factors are detailed in chapter 4 of the Document de Base.

Notice
This announcement does not, and shall not under any circumstances, constitute a public offering or an invitation to the public in connection with any offer of securities. No public offering of securities will be conducted in France or abroad prior to the delivery by the AMF of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE.

The publication of this press release in certain countries may violate applicable regulations. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia or Japan. This document is not an offer for sale of the shares of CARMAT in the United States. The shares of CARMAT may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. CARMAT does not intend to register any portion of the offering in the United States or to conduct a public offering of the shares in the United States.

This document contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de base, changes in economic conditions, the financial markets or the markets in which CARMAT operates.